Francesco has a PhD in Biological Science from the prestigious University of “Federico II” in Naples, Italy. His academic pursuits further extend to a master's degree in Applied Biology and a master's in Big Data and Business Analytics from EAE Business School, Barcelona, Spain, reflecting his commitment to integrating data analytics into biological research.
Francesco's academic career is marked by groundbreaking contributions to liver disease research. His involvement in advancing OCR-002 into critical clinical phases for hepatic encephalopathy, liver cirrhosis, and liver failure has been pivotal. His work within the Yaqrit pipeline significantly advanced Dialive into Phase 2 alongside the TLR4 Antagonist. Notably, his research played a crucial role in biomarker discovery, particularly in identifying ammonia as an early detection biomarker for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This work not only showcased his innovative approach but also his dedication to early disease detection and patient care.
Research Keywords & Expertise
Biomechanics
Nanotechnology
Self-assembly
Structures
3D printing
Genetic tools
Cell sources
Novel chemistries
Fingerprints
Structures
Short Biography
Francesco has a PhD in Biological Science from the prestigious University of “Federico II” in Naples, Italy. His academic pursuits further extend to a master's degree in Applied Biology and a master's in Big Data and Business Analytics from EAE Business School, Barcelona, Spain, reflecting his commitment to integrating data analytics into biological research.
Francesco's academic career is marked by groundbreaking contributions to liver disease research. His involvement in advancing OCR-002 into critical clinical phases for hepatic encephalopathy, liver cirrhosis, and liver failure has been pivotal. His work within the Yaqrit pipeline significantly advanced Dialive into Phase 2 alongside the TLR4 Antagonist. Notably, his research played a crucial role in biomarker discovery, particularly in identifying ammonia as an early detection biomarker for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This work not only showcased his innovative approach but also his dedication to early disease detection and patient care.
